Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCapital LeasesCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesGoodwillGoodwill & IntangiblesIntangiblesLiabilities and Shareholders EquityLong-Term Deferred TaxMinority InterestNon-Current AssetsNon-Current Deferred Tax LiabilityNon-Current Deferred Tax LiabilityNon-Current Deffered RevenueOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)ReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShares OutstandingShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Lineage Cell Therapeutics (LCTX) Cash & Equivalents (2016 - 2026)

Lineage Cell Therapeutics has reported Cash & Equivalents over the past 17 years, most recently at $45.3 million for Q1 2026.

  • For Q1 2026, Cash & Equivalents fell 5.45% year-over-year to $45.3 million; the TTM value through Mar 2026 reached $45.3 million, down 5.45%, while the annual FY2025 figure was $46.0 million, 12.06% up from the prior year.
  • Cash & Equivalents for Q1 2026 was $45.3 million at Lineage Cell Therapeutics, down from $46.0 million in the prior quarter.
  • Over five years, Cash & Equivalents peaked at $78.1 million in Q1 2022 and troughed at $11.4 million in Q4 2022.
  • A 5-year average of $38.3 million and a median of $35.4 million in 2023 define the central range for Cash & Equivalents.
  • On a YoY basis, Cash & Equivalents climbed as much as 212.13% in 2023 and fell as far as 80.21% in 2023.
  • Year by year, Cash & Equivalents stood at $11.4 million in 2022, then soared by 212.13% to $35.4 million in 2023, then rose by 15.73% to $41.0 million in 2024, then rose by 12.06% to $46.0 million in 2025, then decreased by 1.5% to $45.3 million in 2026.
  • Business Quant data shows Cash & Equivalents for LCTX at $45.3 million in Q1 2026, $46.0 million in Q4 2025, and $32.2 million in Q3 2025.